CANN GROUP LIMITED — AGM Information 2021

Nov 9, 2021

==> picture [585 x 60] intentionally omitted <==

ASX ANNOUNCEMENT

10 November 2021

AGM Presentation

10 November 2021: In advance of this afternoon’s Annual General Meeting of shareholders to be held at 2:00pm, and in accordance with ASX Listing Rule 3.13.3, Cann Group Limited (CAN:ASX) is pleased to provide a copy of the presentation that will be made to shareholders at the AGM.

This presentation has been authorised for release by the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright NWR Communications +61 451 896 420 matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock Clive Fanning CEO Head of Investor Relations Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 contact@canngrouplimited.com clive.fanning@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouplimited.com | www.satipharm.com

==> picture [595 x 78] intentionally omitted <==

==> picture [340 x 238] intentionally omitted <==

==> picture [340 x 238] intentionally omitted <==

Annual General Meeting 2pm Wednesday 10 November, 2021 Allan McCallum, AO | Chairman Peter Crock | CEO

Disclaimer

This AGM presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 949 739) (Cann).

Summary information

This Presentation contains summary information about Cann and its activities which is current as at the date of this Presentation. The information provided in this Presentation pertaining to Cann and its business assets, strategy and operations is for general informational purposes only.

Future performance

This Presentation contains certain ‘forward looking statements’, including but not limited to projections, guidance on future revenues and other potential synergies and estimates about the future performance of Cann. Forward looking statements can generally be identified by the use of forward-looking words such as, ‘expect’, ‘anticipate’, ‘likely’, ‘intend’, ‘should’, ‘could’, ‘may’, ‘predict’, ‘plan’, ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’ ‘outlook’, ‘guidance’, ‘potential’ and other similar expressions within the meaning of securities laws of applicable jurisdictions.

The forward-looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Cann, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Cann). There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forwardlooking statements. The forward-looking statements are based on information available to Cann as at the date of this Presentation.

Except as required by law or regulation (including the ASX Listing Rules), Cann undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

Past performance

Investors should note that past performance, including any historical information in this Presentation cannot be relied upon as an indicator of (and provides no guidance as to) future Cann performance including future share price performance.

All rights reserved

Several photographs contained in this Presentation are the property of Cann and are protected under copyright laws. No part of this Presentation may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the Company, except in the case of brief quotations embodied in critical reviews and certain other non-commercial uses permitted by copyright law.

==> picture [96 x 34] intentionally omitted <==

Agenda

1 Introduction 2 Chairman’s address 3 CEO’s address 4 Q&A

==> picture [51 x 47] intentionally omitted <==

----- Start of picture text -----

5
----- End of picture text -----

Formal items of business

==> picture [449 x 238] intentionally omitted <==

==> picture [449 x 238] intentionally omitted <==

Our Board & CEO

==> picture [94 x 88] intentionally omitted <==

==> picture [94 x 87] intentionally omitted <==

==> picture [94 x 87] intentionally omitted <==

==> picture [94 x 88] intentionally omitted <==

MR ALLAN MCCALLUM, AO Chairman

MR PHILIP JACOBSEN Deputy Chairman

MR DOUG RATHBONE, AM Non-executive Director MR GEOFF PEARCE Non-executive Director

==> picture [92 x 87] intentionally omitted <==

==> picture [92 x 87] intentionally omitted <==

==> picture [93 x 88] intentionally omitted <==

MS JENNI PILCHER Non-executive Director

MR JOHN SHARMAN Non-executive Director MR PETER CROCK Chief Executive Officer

==> picture [96 x 34] intentionally omitted <==

==> picture [513 x 475] intentionally omitted <==

Formal business of AGM

Item 1 | Financial statements and reports

To receive the financial report, directors’ report and auditor’s report for the Company and its controlled entities for the financial year ended 30 June 2021.

==> picture [842 x 32] intentionally omitted <==

==> picture [842 x 31] intentionally omitted <==

==> picture [513 x 475] intentionally omitted <==

Chairman’s address

Allan McCallum, AO

==> picture [164 x 119] intentionally omitted <==

Corporate growth

GROWTH STRATEGY SUPPORTED BY INVESTORS Capital raisings pave the way for Cann’s fully integrated supply chain strategy. TIER 1 BANK DEBT FINANCE Secured $50m debt facility with NAB.

DEVELOPING AN END-TO-END CAPABILITY Cann to deliver cultivation, testing, drying, extraction, formulation and more.

==> picture [96 x 34] intentionally omitted <==

SATIPHARM ACQUISITION POSITIONS CANN TO:

• Access rapidly growing CBD markets.

Satipharm

• Fast-track development of THC medicinal cannabis products.

• Become an Australian leader in the over-the-counter low-dose CBD market.

==> picture [220 x 65] intentionally omitted <==

==> picture [96 x 34] intentionally omitted <==

==> picture [164 x 119] intentionally omitted <==

World class facilities

==> picture [164 x 119] intentionally omitted <==

MILDURA FACILITY IS NEARING COMPLETION Large scale, medical grade, cGMP manufacturing facility.

FOCUS ON IMPROVED EFFICIENCIES & INNOVATION UPGRADE AT SOUTHERN FACILITY

==> picture [96 x 34] intentionally omitted <==

IUVO THERAPEUTICS

• Partnership established with iuvo, a leading German importer & distributor.

Global demand

==> picture [164 x 158] intentionally omitted <==

• Cann delivered first shipment of 20,000 units.

REGULATORY CHANGES & EVIDENCE CONTINUES TO EVOLVE GROWTH IN DEMAND EXPECTED TO CONTINUE

==> picture [96 x 34] intentionally omitted <==

==> picture [513 x 475] intentionally omitted <==

CEO’s address Peter Crock

==> picture [200 x 134] intentionally omitted <==

==> picture [200 x 134] intentionally omitted <==

==> picture [200 x 134] intentionally omitted <==

Establishes Cann’s capabilities and scale related efficiencies. Cultivation, GMP extraction, manufacturing and analytical laboratory. Aiming to be an employer of choice in the Sunraysia region.

Mildura nears completion

==> picture [278 x 119] intentionally omitted <==

UPGRADE AT SOUTHERN FACILITY ENABLES CGMP PACKED FLOWER

Upgrades & commercial

==> picture [169 x 119] intentionally omitted <==

B2B STRATEGY CONTINUES WITH EUROPE/UK FOCUS MULTIPLE REVENUE OPPORTUNITIES WITH LOCAL CUSTOMERS

==> picture [96 x 34] intentionally omitted <==

OPENS B2C OPPORTUNITY CAPSULE TECHNOLOGY TO PROMOTE CONFIDENCE

Satipharm

FAST TRACKS DEVELOPMENT OF THC-BASED FORMULATIONS

S3 OVER-THE-COUNTER OPPORTUNITY PROGRESSING

==> picture [96 x 34] intentionally omitted <==

==> picture [168 x 96] intentionally omitted <==

RESEARCH PROGRAMS ENSURE CANN IS LEADING INNOVATION IN THE SECTOR:

• Agriculture Victoria – genetics

R&D partnerships

• La Trobe University – nutrition requirements

• NSW DPI – cultivation techniques

• CSIRO – cannabinoid isolation & manufacturing

• Monash Medicines Innovation Centre – novel formulation & new IP

• Olivia Newton John Cancer Research Institute, La Trobe School of Cancer Medicine & Austin Health – trial in advanced cancer patients

==> picture [168 x 95] intentionally omitted <==

• Murdoch Children’s Research Institute – study into severe Tourette’s syndrome

==> picture [96 x 34] intentionally omitted <==

Outlook FY22

==> picture [169 x 119] intentionally omitted <==

CONTINUALLY GROWING ACCEPTANCE OF MEDICINAL CANNABIS MILDURA FACILITY COMMISSIONING BRINGING VARIOUS NEW OPPORTUNITIES FOCUS ON DELIVERY FOR ALL STAKEHOLDERS

==> picture [96 x 34] intentionally omitted <==

==> picture [513 x 475] intentionally omitted <==

Q&A

==> picture [513 x 475] intentionally omitted <==

Resolutions for voting

Items 2 to 5

Resolution 2 | Adoption of Remuneration Report

That, pursuant to and in accordance with section 250R(2) of the Corporations Act, the Remuneration Report for the financial year ending 30 June 2021 as set out in pages 23 to 32 (inclusive) of the Annual Report be adopted.

Proxy votes

==> picture [749 x 133] intentionally omitted <==

----- Start of picture text -----

33,661,998 2,355,520 2,035,886 38,053,404 10.91% 160,515
88.46% 6.19% 5.35%
----- End of picture text -----

==> picture [842 x 32] intentionally omitted <==

==> picture [842 x 31] intentionally omitted <==

Resolution 3 | Re-election of Director

That Mr Doug Rathbone, a Director who retires from office in accordance with Rule 50.2 of the Company’s Constitution and being eligible for re-election, be re-elected a Director of the Company.

Proxy votes

==> picture [749 x 132] intentionally omitted <==

----- Start of picture text -----

52,615,955 3,151,675 1,176,980 56,944,610 16.32% 196,488
92.40% 5.53% 2.07%
----- End of picture text -----

==> picture [842 x 32] intentionally omitted <==

==> picture [842 x 31] intentionally omitted <==

Resolution 4 | Re-election of Director

That Mr John Sharman, a Director who was appointed to fill a casual vacancy in accordance with Rule 49.1 of the Company’s Constitution until this Annual General Meeting and being eligible for re-election, be re-elected a Director of the Company.

Proxy votes

==> picture [749 x 132] intentionally omitted <==

----- Start of picture text -----

52,748,053 3,151,948 1,046,859 56,946,860 16.32% 194,238
92.63% 5.53% 1.84%
----- End of picture text -----

==> picture [842 x 32] intentionally omitted <==

==> picture [842 x 31] intentionally omitted <==

Resolution 5 | Approval of amendments to Constitution

That, in accordance with section 136(2) of the Corporations Act the Constitution of the Company be amended as set out in the amended Constitution tabled at the Annual General Meeting convened by this Notice of Annual General Meeting and signed by the Chairman of the meeting for the purpose of identification.

Proxy votes

==> picture [749 x 132] intentionally omitted <==

----- Start of picture text -----

52,404,277 3,167,974 1,278,510 56,850,761 16.30% 290,337
92.18% 5.57% 2.25%
----- End of picture text -----

==> picture [842 x 32] intentionally omitted <==

==> picture [842 x 31] intentionally omitted <==

Meeting close

CONTACTS

Clive Fanning Head of Investor Relations

Cann Group Limited

+61 3 9095 7088

contact@canngrouplimited.com

Matthew Wright Investor / Media Relations

NWR Communications +61 (0)451 896 420

matt@nwrcommunications.com.au